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Conditioned media from osteosarcoma cells up-regulated MC3T3-E1 osteoblastic 
cell proliferation via JAKs and PI3-K/Akt signal crosstalk  
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Summary 
The maintenance of bone mass requires a strict balance between bone formation 
by osteoblasts and bone resorption by osteoclasts. In tumoral bone environment, tumor 
cells frequently disturb this balance by interaction with bone cells to create a favorable 
site for tumor growth, and to promote pathological bone changes. Thus, elucidation of the 
mechanisms underlying interactions between tumor cells and bone cells might eventually 
lead to a more rational strategy for therapeutic intervention. In this study, the effects of 
mouse osteosarcoma cells on mouse pre-osteoblastic cells were determined by 
assessement of cell viability, osteoblastic differentiation and signal transduction 
pathways. MOS-J/POS-1 conditioned media (CMs) significantly induced MC3T3-E1 
cell proliferation in a dose-dependent manner and reduced both alkaline phosphatase 
activity as well as mineralized nodule formation. Piceatannol, AG490, LY294002 and 
rapamycin significantly abrogated this up-regulated cell proliferation; however UO126 
and STAT3 inhibitor peptide did not affect this up-regulated cell proliferation. 
MOS-J/POS-1 CMs activated ERK 1/2, STAT3 and Akt signal transduction pathways; 
however MOS-J/POS-1 CMs-induced pro-proliferating signal was transmitted via Akt 
not via the ERK 1/2 and STAT3 pathway. Furthermore, Western blots clearly revealed 
novel signal crosstalk between JAKs and PI3-K/Akt in osteoblastic cells. The specific 
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factor(s) involved in MOS-J/POS-1 CMs-induced MC3T3-E1 cell proliferation via 
JAKs/PI3-K/Akt/mTOR pathway remain(s) to be determined. Determination of the 
specific factor(s) that participate in pro-proliferating JAKs and PI3-K/Akt signal 
crosstalk will offers new insight to understand osteosarcoma, as well as other 
bone-related diseases. 
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Introduction 
Osteosarcoma is the most common form of primary malignant bone tumor 
typically affecting children and young adults [1]. Approximately 1000 new cases are seen 
per year in North America and a similar number occurs in Europe [2]. In spite of the 
dramatic improvement of the prognosis with aggressive chemotherapy in non-metastatic 
osteosarcoma [2], patients with metastasis and/or chemotherapy-resistant osteosarcoma 
have poor outcomes [3]. Therefore, alternative treatment that improves survival of the 
patients with osteosarcoma is critically needed. Better understanding of disease 
pathogenesis is essential to devise new therapeutic arms; however the role of 
osteosarcoma growth and cellular biology in bone microenvironment are not fully 
understood. 
Bone remodeling (bone formation and bone resorption) is tightly regulated 
soluble, membranous and matrix factors. Pathological bone remodeling can be 
considered as a consequence of imbalance between osteoblast and osteoclast activity. In 
osteolytic bone metastases, this hypothesis has been well addressed. Thus, the 
establishment of the interaction between bone cells and tumor cells is considered as a 
persuasive explanation of tumor growth in bone [4]. These findings suggest that bone 
environment established by interaction of bone cells with tumor cells plays a pivotal role 
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in bone tumor development. In this context, osteosarcoma development might also create 
a favorable environment for tumor growth by complex interaction with bone cells and 
ultimately determine its osteogenic profile. Thus, the elucidation of the mechanisms 
implicated in disturbed bone remodeling by osteosarcoma cells could eventually offer 
new insight to understanding not only osteosarcoma, but also bone cellular biology. 
In the present study, we investigated the effects of mouse osteosarcoma cell lines, 
MOS-J and POS-1 on mouse pre-osteoblastic cells to reveal the significant role of 
osteosarcoma cells in bone environment. 
Materials and methods 
Cell culture 
 MOS-J [5] and POS-1 [6, 7] cell lines were derived from spontaneous mouse 
osteosarcoma. MOS-J was obtained from The Jackson laboratory (ME, USA) and 
POS-1 was kindly provided by Dr. A. Kamijo (Kanagawa Cancer Center, Kanagawa, 
Japan). MOS-J and POS-1 cells express respectively osteogenic and undifferentiated 
phenotype. MC3T3-E1, a mouse calvaria-derived pre-osteoblast cell line was obtained 
from the RIKEN Cell Bank (Tsukuba, Japan). These cell lines were cultured in RPMI 
1640 (Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (FBS, 
Hyclone, Brebières, France), at 37°C in a humidified atmosphere containing 5% CO2. 
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The medium was changed twice a week and adherent cells were harvested using 0.05% 
trypsin-0.02% EDTA solution (Lonza). 
Preparation of osteosarcoma conditioned medium 
MOS-J and POS-1 conditioned media (MOS-J CM, POS-1 CM) were prepared 
as previously described with slight modifications [8]. MOS-J or POS-1 cells (104 
cells/cm2) were grown in a 25cm2 flask until 70-80% confluence in RPMI 1640 
supplemented with 10% FBS. Then, cells were washed three times with phosphate 
buffered saline (PBS, Lonza) and the medium was changed into serum-free RPMI 1640. 
After 24 h, CMs were collected and centrifuged at 1000 rpm for 10 min and stored at 
-80°C until use. The same volume of serum-free RPMI 1640 in the same conditions 
without cells was used as a control CM (CT CM). 
Cell viability assays 
-XTT test 
The proliferation of mouse pre-osteoblast MC3T3-E1 cells was determined as 
previously reported with some modifications [8]. MC3T3-E1 cells were seeded into a 
96-multiwell plate (2.8 x 103 cells/well) and cultured for 72 h in CT CM or MOS-J/POS-1 
CMs supplemented with 5% FBS. The media were changed every 48 h and cell 
proliferation was determined by a sodium 3′ 
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[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic 
acid hydrate (XTT) based method using Cell Proliferation Kit II (Roche Applied Science, 
Mannheim, Germany) following the supplier’s recommendations. 
Take into account of the result of signal transduction analyses in this study as 
well as the common knowledge that MEK/ERK, Janus kinases (JAKs), signal transducer 
and activator of transduction (STAT), phosphatidylinositol 3-kinase (PI3-K) and 
mammalian target of rapamycin (mTOR) pathways were frequently implicated in cell 
proliferation; the following inhibitors were tested: MEK/ERK inhibitor (UO126, 10 µM, 
Calbiochem, CA, USA), a JAK1 inhibitor (piceatannol, 10 µM, Calbiochem), a JAK2 
inhibitor (AG490, 20 µM, Calbiochem), a JAK3 inhibitor (JAK3 Inhibitor I, 10 µM, 
Calbiochem), a STAT3 inhibitor (STAT3 inhibitor peptide, 50 µM, Calbiochem), a 
PI3-K inhibitor (LY294002, 20 µM, Calbiochem) and a mTOR inhibitor (rapamycin, 10 
nM, Calbiochem). These inhibitors were tested to identify which signal transduction 
pathway plays a crucial role in MOS-J/POS-1 CMs-induced MC3T3-E1 cell proliferation. 
These inhibitors were added 1 h before of the treatment by osteosarcoma CMs except for 
AG490 that was added 16 h before. All inhibitors were maintained until the end of culture 
period at the indicated concentrations. In addition, several neutralizing antibodies were 
also tested to detect the specific factor(s) that play a pivotal role in MOS-J/POS-1 
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CMs-induced MC3T3-E1 cell proliferation in the same experimental conditions except 
for the concentrations of CMs (50% vol/vol were used). Anti-mouse interleukin (IL)-6 
receptor antibody (anti-IL-6R, 10 µg/ml, R&D systems, MN, USA), anti-mouse IL-11 
receptor antibody (anti-IL-11R, 100 µg/ml, R&D systems), anti-mouse gp130 antibody 
(anti-gp130, 20 µg/ml, R&D systems), anti-mouse insulin-like growth factor (IGF)-I 
antibody (anti-IGF-I, 20 µg/ml, R&D systems) and anti-mouse IGF-II antibody 
(anti-IGF-II, 20 µg/ml, R&D systems) were assessed. Anti-goat IgG (10, 20, 100 µg/ml, 
R&D systems) was used as a control. These antibodies were pre-incubated for 1 h at 37°C 
with MC3T3-E1 cells or MOS-J/POS-1 CMs and maintained during the culture period at 
the indicated concentrations.  Recombinant human epidermal growth factor (rhEGF, 100 
ng/ml, R&D systems), human growth hormone (rhGH, 100 ng/ml, Lilly France, France), 
human IL-6 (rhIL-6, 100 ng/ml, R&D systems) alone or association with human soluble 
IL-6R (rhIL-6Rs:rhIL-6 = 500 ng/ml:100 ng/ml, R&D systems), human IL-11 (rhIL-11, 
100 ng/ml, R&D systems), human leukemia inhibitory factor (rhLIF, 100 ng/ml, R&D 
systems) and human IGF-I (rhIGF-I, 100 ng/ml, R&D systems) were employed and 
MC3T3-E1 cell proliferation was determined in the presence or the absence of these 
factors. 
- Trypan blue exclusion 
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Trypan blue exclusion was used to quantify all viability. MC3T3-E1 cells were 
seeded into a 24-multiwell plate (5 x 103 cells/well) and cultured in CT CM or 
MOS-J/POS-1 CMs supplemented with 5% FBS, then the viable and dead cell numbers 
were determined at day 1, 4 and 7. Furthermore, under the same experimental conditions, 
MC3T3-E1 cells were cultured in the presence or the absence of suramin, a pan-growth 
factor blocker (50-200 µg/ml, Sigma-Aldrich, St. Louis, MO, USA). MC3T3-E1 cell 
proliferation was measured by direct cell counting using the trypan blue exclusion 
method, as suramin may interfere with cell proliferation assays based on mitochondrial 
enzyme activity [9]. 
Signal transduction analyses by Western Blot  
Signal transduction analyses were performed as previously described with slight 
modifications [8]. Briefly, MC3T3-E1 cells were seeded (104 cells/cm2) into a 
6-multiwell plate in RPMI 1640 supplemented with 10% FBS. At 70-80% of confluence, 
MC3T3-E1 cells were washed three times with serum-free RPMI 1640 and serum starved 
for 24 h, and then the cells were incubated for 30 min with CT CM. After that MC3T3-E1 
cells were incubated for 2, 5, 10, 15 and 30 min in the presence or the absence of 
MOS-J/POS-1 CMs. In the experiments designed to determine the responsible signal 
transduction pathway for MOS-J/POS-1 CMs-induced cell proliferation, several signal 
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transduction inhibitors were used as described above. After pre-treatment with these 
inhibitors, MC3T3-E1 cells were then cultured in the presence or the absence of 
MOS-J/POS-1 CMs for 15 min. In addition, to elucidate the signal transduction pathways 
activated by IL-6 family cytokines (rhIL-6 alone, rhIL-6+rhIL-6Rs, rhIL-11 and rhLIF), 
MC3T3-E1 cells were similarly treated for 15 min in the presence of these cytokines at 
the same concentrations as described above. After the treatments, the cells were lysed in 
ice-cold buffer (NaCl 150 mM, Tris 50 mM, Nonidet P-40 1%, sodium deoxycholate 
0.25%, NaF 1 mM, NaVO4 1 mM, leupeptine 10 mg/ml, aprotinin 10 mg/ml, PMSF 0.5 
mM) and same amounts of proteins were subjected to the study. The induction of the 
phosphorylated forms of ERK 1/2 (Thr202/Tyr204), p38 (Thr180/Tyr182), STAT1 
(Tyr701), STAT3 (Tyr705) (Cell Signaling Technologies, MA, USA), STAT5 (Tyr694, 
ZYMED Laboratories, CA, USA), Akt (Ser473) and mTOR (Ser2448, Cell Signaling 
Technologies) were determined as well as total forms of ERK 1/2 (Cell Signaling 
Technologies), p38 (R&D systems), STAT1, STAT3, STAT5 (BD Biosciences, CA, 
USA), Akt and actin (Cell Signaling Technologies) according to the manufacture’s 
instructions, and revealed using the SuperSignal West Pico Chemiluminescent Substrate 
(Pierce Biotechnology, Rockford, USA). 
Characterization of mouse osteosarcoma cell lines 
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- RNA extraction and semi-quantitative RT-PCR analysis 
Total RNA was extracted from the mouse osteosarcoma cell lines using TRIzol 
reagent (Invitrogen, Eragny, France) following manufacturer’s recommendations. First, 
total RNA (5 µg) was reverse transcribed (RT) into cDNA using 400 U MMLV-RT 
(Invitrogen) and 0.5 µg random primers (Promega, WI, USA). Two microliters of the RT 
products were subjected to PCR using 1.25 U of Ampli Taq Gold (Applied Biosystems, 
CA, USA) and upstream and downstream primers (20 pmol each) to determine the 
expression of IL-6 [5’-ccggagaggagacttcacag-3’ (sense), 5’-ggaaattggggtaggaagga-3’ 
(anti-sense)], IL-11 [5’-tgtggggacatgaactgtgt-3’ (sense), 5’-tactcgaagccttgtcagca-3’ 
(anti-sense)], IGF-I [5’-tggatgctcttcagttcgtg-3’ (sense), 5’-gtcttgggcatgtcagtgtg-3’ 
(anti-sense)], IGF-II [5’-ggaagtcgatgttggtgctt-3’ (sense), 5’-cgtttggcctctctgaactc-3’ 
(anti-sense)], LIF [5’-acggcaacctcatgaaccaga-3’ (sense), 5’-ctagaaggcctggaccaccac-3’ 
(anti-sense)], oncostatin M (OSM) [5’-cctgaacacacctgacctga-3’ (sense), 
5’-cgatggtatccccagagaaa-3’ (anti-sense)] and 18S [5’-tcaagaacgaaagtcggaggtc-3’ (sense), 
5’-ttattgctcaatctcgggtggct-3’ (anti-sense)]. The thermal cycle profile was as follows: 
denaturation for 30 sec at 95°C, annealing for 30 sec at 60°C (IL-11, IGF-I, IGF-II) and 
62°C (IL-6, LIF, OSM, 18S) respectively, and extension for 60 sec at 72°C. After the 
number of PCR cycles was increased, a plot was done for each sample and the cycle 
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values corresponding to the linear part of the amplification curve were determined and 
used to quantify the messages versus the 18S signal determined in the same way. The 
cycle number used was 30 cycles for IL-6, LIF, 35 cycles for IL-11, OSM, IGF-I, IGF-II 
and 20 cycles for 18S, respectively. The PCR products were electrophoresed on 1% 
agarose gel and stained by GelRed (Biotium, CA, USA). The mRNA levels of each gene 
were standardized to 18S levels. 
Osteoblastic differentiation assay 
- Alkaline phosphatase (ALP) activity 
Alkaline phosphatase (ALP) activity was determined in of mouse calvaria 
osteoblasts and MC3T3-E1 cells as previously reported with slight modifications [8]. 
Briefly, primary cultured mouse calvaria osteoblasts isolated as previously described [10] 
or MC3T3-E1 cells were seeded into a 24-multiwell plate (5 x 103 cells/well) in CT CM 
or MOS-J/POS-1 CMs supplemented with 5% FBS in the presence of 50 µg/ml ascorbic 
acid (Sigma-Aldrich). Culture medium was changed every 48 h for 7 days. At the end of 
the culture period, the cells were lyzed in ice-cold buffer [NaCl 150 mM, Tris 50 mM, 
Nonidet P-40 1%, sodium deoxycholate 0.25%, NaF 1 mM, leupeptine 10 mg/ml, 
aprotinin 10 mg/ml, PMSF 0.5 mM]. ALP activity was determined by U/µg protein using 
Enzyline PAL optimisé (bioMérieux, Marcy-l’Etoile, France) according to the supplier’s 
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instructions. 
- Mineralization assay 
Alizarin red-S staining was used to detect the in vitro formation of mineralized 
nodule as previously reported with slight modifications [8]. In brief, mouse calvaria 
osteoblasts were seeded (104 cells/cm2) into a 24-multiwell plate in CT CM or 
MOS-J/POS-1 CMs supplemented with 10% FBS containing 10-8 M dexamethasone 
(Sigma-Aldrich), 50 µg/ml ascorbic acid and 10 mM Na-β-glycerophosphate 
(Sigma-Aldrich). The culture medium was changed every 48 h for 2.5 weeks. Using 
similar experimental conditions, MC3T3-E1 cells were maintained for 4.5 weeks. 
Adherent cells were washed with PBS, and then fixed by ice-cold 70% ethanol for 1 h. 
The fixed cells were washed with distilled water and incubated with alizarin red-S (Merck 
KGaA, Darmstadt, Germany, 40 mM, pH 7.4) for 10 min at room temperature. After 
extensive washing, the mineralized nodules were counted by light microscope in three 
random fields and were averaged for each condition. 
 
 
Statistical analyses 
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Represented data are the results of three independent studies at least. 
Mann-Whitney’s U test was used to assess differences in experimental groups. P values 
less than 0.05 were considered statistically significant. 
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Results 
-Soluble factor(s) produced by MOS-J/POS-1 cells stimulated MC3T3-E1 cell 
proliferation 
To determine whether osteosarcoma cells produce soluble factor(s) modulating 
bone cell survival and proliferation, osteoblast proliferation was analyzed in the presence 
of CMs from osteosarcoma cells. MOS-J/POS-1 CMs induced a significant up-regulation 
of MC3T3-E1 cell proliferation in a dose-dependent manner (Figure 1A: MOS-J, B: 
POS-1). MOS-J CM induced around 20 % higher MC3T3-E1 cell proliferation compared 
to that of POS-1 CM (Figure 1A-D). Furthermore, soluble factor(s) secreted from MOS-J 
and POS-1 acted as survival factor(s) of MC3T3-E1 cells by increasing alive cell 
percentage (Figure 1E) and decreasing cell death (Figure 1F). 
To identify the factor(s) associated with the up-regulation of pre-osteoblast 
proliferation, the effects of several signal transduction inhibitors and cytokines/growth 
factors were assessed in the MC3T3-E1 proliferation assay. Suramin, a pan-growth factor 
blocker, significantly and dose-dependently abrogated the up-regulated MC3T3-E1 cell 
proliferation induced by MOS-J CM (Figure 2A) and POS-1 CM (Figure 2B). This 
up-regulation was also abolished in the presence of piceatannol, AG490, LY294002 or 
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rapamycin (Figure 2C), whereas both UO126 and STAT3 inhibitor peptide had no 
significant effect (Figure 2D). 
-MOS-J/POS-1 CMs activate ERK 1/2, STAT3, Akt and mTOR signal transduction 
pathways in MC3T3-E1 pre-osteoblast cell 
When MC3T3-E1 cells were incubated in the presence of MOS-J/POS-1 CMs, 
an overt activation (phosphorylation) of ERK 1/2, STAT3 and Akt were observed after 
around 2 and 5 min and reached a plateau after 10 min for ERK1/2, 15 min for STAT3 
and Akt, respectively (Figure 3A). Clear activation of mTOR by MOS-J/POS-1 CMs was 
also confirmed after 30 min incubation (Figure 3B) and no activation of p38, STAT1 and 
STAT5. LY294002 was evidenced. Furthermore, piceatannol and AG490 completely 
abolished Akt phosphorylation (Figure 3C); while JAK3 inhibitor I did not affect Akt 
phosphorylation in MC3T3-E1 cells (Figure 3C). Similar to JAK3 inhibitor I, UO126 did 
not affect the MOS-J/POS-1 CMs-induced Akt status (data not shown). 
As the JAK/STAT signaling pathway was activated in MC3T3-E1 cells by 
MOS-J/POS-1 CMs, we analyzed the mRNA expression, of IL-6 family cytokines wich 
ar known to activate JAKs/STATs pathway, by osteosarcoma cell. Both MOS-J and 
POS-1 cells expressed IL-6, IL-11 and LIF transcripts, but not OSM. Therefore, STAT3 
and Akt activation by these IL-6 family cytokines expressed by MOS-J/POS-1 cells were 
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studied. These cytokines did not induce Akt phosphorylation, whereas STAT3 was 
clearly activated. As previous reported [11], IL-6 can remarkably activate STAT3 in 
association with its soluble receptor; however STAT3 phosphorylation was slightly 
induced by IL-6 alone. IL-6 family cytokines-induced STAT3 phosphorylation was 
significantly abrogated in the presence of anti-gp130. Furthermore, neither all 
recombinant cytokines/growth factors tested (rhEGF, rhGH, rhIL-6, rhIL-6+rhIL-6Rs, 
rhIL-11, rhLIF, rhIGF-I) nor neutralizing antibodies (anti-IL-6R, anti-IL-11R, anti-gp130, 
anti-IGF-I, anti-IGF-II) did not allow to identify the factor produced by MOS-J/POS-1 
cells and associated with MC3T3-E1 cell proliferation (data not shown). 
-MOS-J/POS-1 cell effects on osteoblastic differentiation 
ALP activity of MC3T3-E1 cells was significantly reduced by MOS-J/POS-1 
CMs treatment compared to the CT CM [CT CM vs MOS-J/POS-1 CMs (mean ± SD, 
U/µg protein): 0.44 ± 0.064 vs 0.20 ± 0.043/ 0.23 ± 0.078, p=0.02]; however there was no 
significant difference between MOS-J CM and POS-1 CM (p=0.77). In addition, 
MOS-J/POS-1 CMs significantly reduced mineralized nodule formed by MC3T3-E1 
cells compared to CT CM [CT CM vs MOS-J/POS-1 CMs (mean ± SD): 41 ± 14 vs 11 ± 
5/ 5 ± 4, p=0.0039] (Figure 4). MOS-J CM induced clearly bigger and greater number of 
mineralized nodules compared to those of POS-1 CM (MOS-J CM vs POS-1 CM: 11 ± 5 
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vs 5 ± 4, p=0.045) (Figure 4). The induction of small mineralized nodules was scarcely 
observed in the presence of POS-1 CM. The congruent data were observed in the culture 
of mouse calvaria osteoblasts (data not shown). 
Discussion 
In the present study, we first evidenced that the conditionned media of 
MOS-J/POS-1 osteosarcoma cells modulated MC3T3-E1 cell viability and exerted a 
dose-dependent stimulatory effect on cell proliferation. As suramin, a pan-growth factor 
blocker, dose-dependently inhibited the effect of MOS-J/POS-1 CMs on MC3T3-E1 cell 
proliferation, we considered that MOS-J/POS-1 cells produced more than one growth 
factor which drastically up-regulated MC3T3-E1 cell proliferation. 
Interestingly, the present results demonstrated that JAKs/PI3-K/Akt/mTOR 
pathway, not ERK 1/2 and STAT3, played a crucial role in the effects of MOS-J/POS-1 
CMs. Moreover, clear signal crosstalk between JAK1, 2 and PI3-K/Akt cascades was 
revealed and PI3-K/Akt was downstream target of JAKs (Figure 5). To the best of our 
knowledge, this is the first report of JAKs and PI3-K/Akt signal crosstalk in osteoblastic 
cells. Such signal crosstalk has been reported as an optimal anti-apoptotic and 
pro-proliferating signal in other tumor cell types, including multiple myeloma cells 
[12-14], hepatoma cells [15] and basal cell carcinoma cells [16]. In agreement with these 
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reports, this signal also played an essential role in dramatically up-regulated MC3T3-E1 
pre-osteoblast cell proliferation. 
Upstream signaling between cytokine/growth factor receptors and PI3-K is not 
fully determined. JAKs are implicated in cytokines/growth hormones signaling and are 
crucial components of diverse signal transduction pathways that govern cellular survival, 
proliferation, differentiation and apoptosis [17]. While the STATs are well known and the 
most investigated downstream target of JAKs, other targets of JAKs have been identified 
[17]. Indeed, emerging evidence has revealed that JAK kinase function is required for 
optimal activation of the Src-kinase cascade, the Ras-MAP kinase pathway and the 
PI3-K/Akt pathway [17]. In JAKs-induced PI3-K activation, several studies have 
reported the involvement of the p85 subunit of PI3-K [18], insulin-receptor substrate 
(IRS) proteins (IRS-1, IRS-2 and IRS-3) [19] and gp130 subunit [20]. Taken together, 
these studies indicate that the cellular signal transduction machinery is programmed to 
respond to changes in stimuli by integrating diverse signaling pathways and thus to 
generate an orchestrated response. In these previous reports, IL-6 family cytokines 
functioned as an activator of JAKs and PI3-K crosstalk [12-16, 20]. We have therefore 
carefully examined IL-6 family cytokines. Thus, IL-6, IL-11, LIF, OSM but also EGF, 
GH, IGF-I and IGF-II have been excluded and did not appear responsible for the effects 
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of CMs observed on osteoblastic cells and the specific factor(s) remain to be determined. 
It is likely that these cytokine/growth hormone cocktails can uniquely support 
pro-proliferating effects on pre-osteoblast cells via JAKs and PI3-K signal crosstalk by 
their synergic effect. It has been reported that the rate of bone formation and resorption is 
largely determined by the numbers of bone-forming (osteoblast) and bone-resorbing 
(osteoclast) cells responsible for the regeneration of the adult skeleton [21]. Thus, the 
determination of the specific factor(s) and optimal pre-osteoblast cell pro-proliferating 
signals undoubtedly will lead to unprecedented therapeutic approach for bone-loss 
diseases such as osteoporosis. The JAKs and PI3-K signal crosstalk is a good candidate of 
such signals. 
MOS-J/POS-1 CMs significantly reduced mineralized nodule formations in 
pre-osteoblastic cells; however MOS-J CM could induce bigger and greater number of 
mineralized nodules compared to those induced by POS-1 CM. MOS-J model mice [5] 
demonstrated clearly more osteogenic tumors compared to the POS-1 model [7]. Thus, 
our findings can explain, at least in part, the increased osteogenic profile of MOS-J 
model. 
In conclusion, the present study reveals clear interaction of osteosarcoma cells 
with bone cells. The pre-osteoblast cell proliferation induced by osteosarcoma cells may 
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play, at least in part, a role into the osteoblastic profile of osteosarcoma patients. 
Furthermore, novel JAKs and PI3-K/Akt signal crosstalk that induces pre-osteoblast cell 
proliferation, one of the principal results obtained from the present study, will offer novel 
insight into the osteosarcoma biology as well as therapeutic capability for all bone-loss 
diseases such as osteoporosis. 
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Figure legends 
Figure 1. MOS-J/POS-1 conditioned media (CMs) significantly up-regulated 
MC3T3-E1 cell proliferation.  
The mouse pre-osteoblast MC3T3-E1 cells were cultured for 72 h with control CM (CT 
CM) or MOS-J/POS-1 CMs supplemented with 5% FBS as described in the Materials and 
Methods section. Cell proliferation was determined using a XTT based method. CM from 
both MOS-J (A) and POS-1 (B) cells drastically up-regulated MC3T3-E1 cell 
proliferation in a dose-dependent fashion. Manual viable cell counting with trypan blue 
exclusion revealed that MOS-J/POS-1 CMs induced MC3T3-E1 cell proliferation (C) 
and reduced cell death (D) resulted in an increase of alive cell percentage (E) and a 
decrease of dead cell percentage (F).  
*: p<0.004, **: p<0.0001 by a Mann-Whitney’s U test (CT CM vs CMs) 
 
Figure 2. MC3T3-E1 cell proliferation tests with suramin or several signal 
transduction inhibitors. 
Manual cell counting with trypan blue exclusion revealed that suramin, a pan-growth 
factor blocker, attenuated the effect of MOS-J/POS-1 CMs on MC3T3-E1 cell 
proliferation from 4 days of culture in a dose-dependent fashion. (A) MOS-J CM, (B) 
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POS-1 CM, *: p<0.004 by a Mann-Whitney’s U test (CMs vs others) CT CM: control CM, 
s50: suramin 50 µg/ml, s100: suramin 100 µg/ml, s200: suramin 200 µg/ml 
(C) The high proliferation rate of MC3T3-E1 cells induced by MOS-J/POS-1 CMs was 
reduced to the basal level in the presence of a Janus kinase (JAK) 1 inhibitor (piacetannol, 
10 µM), a JAK2 inhibitor (AG490, 20 µM), a phosphatidylinositol 3-kinase (PI3-K) 
inhibitor (LY294002, 20 µM) or a mammalian target of rapamycin (mTOR) inhibitor 
(rapamycin, 10 nM). (D) Both an ERK 1/2 inhibitor (UO126) and a STAT3 inhibitor 
(STAT3 inhibitor peptide) had no significant effect. **: p<0.001 by a Mann-Whitney’s U 
test (vs respective CM) 
 
Figure 3. Results of signal transduction analyses by Western blot.  
(A) MC3T3-E1 cells were prepared as described in the Materials and Methods section 
and then incubated for 30 min with control conditioned media (CT CM). MC3T3-E1 cells 
were then incubated for 2, 5, 10, 15 and 30 min in the presence or absence of MOS-J (left 
panel)/POS-1 (right panel) CMs. (B) MOS-J/POS-1 CMs significantly activated mTOR 
after 30 min incubation. (C) A phosphatidylinositol 3-kinase (PI3-K) inhibitor 
(LY294002, 20 µM) completely abrogated MOS-J/POS-1 CMs-induced Akt 
phosphorylation. A Janus kinase (JAK) 1 inhibitor (piacetannol, 20 µM) and a JAK2 
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inhibitor (AG490, 20 µM) also completely abrogated MOS-J/POS-1 CMs-induced Akt 
phosphorylation; however a JAK3 inhibitor (JAK3 inhibitor I, 20 µM) had no effect on 
Akt phosphorylation. 
 
Figure 4. Representative mineralized nodules induced by CT CM and 
MOS-J/POS-1 CMs.  
Mineralized nodule induction was detected by alizarin red-S staining as described in 
Materials and Methods section. MOS-J/POS-1 conditioned media (CMs) significantly 
reduced mineralized nodule formation compared to control CM (CT CM); however 
MOS-J CM induced clearly bigger and greater numbers of mineralized nodules compared 
to those of POS-1 CM. POS-1 CM induced only small mineralized nodules. Original 
magnification: x100 and x400 (inserts), bar: 25 µm 
 
Figure 5. Schematic representation of signaling pathway involved in pre-osteoblast 
proliferation induced by MOS-J/POS-1 CMs .  
MOS-J/POS-1 conditioned media (CMs) induced novel JAK1, 2 and PI3-K signal 
crosstalk in osteoblastic cells. The pre-osteoblast proliferating signal induced by 
MOS-J/POS-1 CMs was transmitted via the JAKs/PI3-K/Akt/mTOR pathway. “Soluble 
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factor(s)”: pre-osteoblast cell pro-proliferating factor(s) produced by osteosarcoma cells. 
Solid line arrow: signaling pathway associated with pre-osteoblast proliferation induced 
by MOS-J/POS-1 CMs. Dotted line arrow: MOS-J/POS-1 CMs-induced but 
non-responsible signals for pre-osteoblast proliferation 
 
Figure 1
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
0 5 25 50 100
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
0 5 25 50 100
A B
D
b
a
MOS-J CM
(% vol/vol)
POS-1 CM 
(% vol/vol)
b
a
a
C
(days)
Vi
ab
le
 
ce
ll 
n
u
m
be
r 
(x1
05
)
0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
0 1 4 7
CT CM
CM MOS-J
CM POS-1
c
c
c
0
0.2
0.4
0.6
0.8
1.0
1.2
0 1 4 7
CT CM
CM MOS-J
CM POS-1
D
ea
d 
ce
ll 
n
u
m
be
r 
(x1
04
)
(days)
c
c
c
c
O
D
 
49
0 
n
m
O
D
 
49
0 
n
m
C**
**
**
****
**
- - - - - +      +       +       +      +      - - - - -
- - +       - - - - +       - - - - +        - -
- - - +       - - - - +       - - - - +       -
- - - - - - - - - - +      +       +       +      + 
MOS-J CM
CT CM
LY294002
piceatannol
AG490
+      +       +      +    +       - - - - - - - - - -
- +        - - - - +       - - - - +       - - -
- - - - +       - - - - +      - - - - +rapamycin
POS-1 CM 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
O
D
 
49
0 
n
m
**
**
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
0 1 4 7
CT CM 
MOS-J CM 
MOS-J CM+s50
MOS-J CM+s100
MOS-J CM+s200
(days)
Al
iv
e 
ce
ll 
n
u
m
be
r 
(x1
05
)
*
*
A
0 1 4 7
CT CM
POS-1 CM 
POS-1 CM+s50
POS-1 CM+s100
POS-1 CM+s200
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
(days)
Al
iv
e 
ce
ll 
n
u
m
be
r 
(x1
05
)
*
*
B
D
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
MOS-J CM
CT CM
STAT3IP
UO126 
POS-1 CM 
+      +       +      - - - - - -
- - - +      +       +       - - -
- - - - - - +       +      +    
- +       - - +        - - +      -
- - +      - - +       - - +   
O
D
 
49
0 
n
m
p-STAT3
A
ERK1/2
p-ERK1/2
STAT3
p-Akt
Akt
Time (min)
MOS-J CM POS-1 CM
0 2 5 15 3010 0 2 5 15 3010
C
p-Akt
Akt
CT CM
Inhibitor 20 µM - +-+-+
MOS-J CM
POS-1 CM - ++---
- --++-
+ ----+
LY249002
piacetannol
- +-+-+
- ++---
- --++-
+ ----+
JAK3 inhibitor I
- +-+-+
- ++---
- --++-
+ ----+
AG490
- ++---
- +-+-+
-
--++-
+ ----+
p-Akt
Akt
CT CM
Inhibitor 10 µM
MOS-J CM
POS-1 CM
actin
p-mTOR
CT CM
Positive CT - +--
MOS-J CM
POS-1 CM - -+-
- --+
+ ---
B
CT CM MOS-J CM POS-1 CM
JAK3
JAK2 
JAK1 
mTOR
STAT3
PI3-K
Akt
LY294002
rapamycin
AG490
piacetannol
Soluble factor(s)
Soluble factor(s)
Pre-osteoblast cell proliferation
ERK
Signal crosstalk
JAK3 Inhibitor I
? ?
UO126STAT3 inhibitorpeptide
JAK3
JAK2 
JAK1 
mTOR
STAT3
PI3-K
Akt
LY294002
rapamycin
AG490
piacetannol
Soluble factors
Soluble factors
Pre-osteoblast Cell proliferation
ERK
Signal crosstalk
JAK3 Inhibitor I
Figure 6
